He is educated in chemistry, pharmacology and toxicology and began his career in forensic science at the Scotland Yard laboratory in England (1956), specializing in toxicology. In 1964, he was appointed Chief Forensic Toxicologist in Santa Clara County in San Jose, California and later lectured in forensic toxicology at the University of California of Criminology at Berkeley. He is currently Chief Consulting Toxicologist to the National Football League, and consultant to the World and U.S. Antidoping Agencies. He is the President and Chairman of the Board for the Sports Medicine Research and Testing Laboratory Inc. He serves on the Board of the NFL Health Foundation; the Scientific Advisory Board of the Partnership for Clean Competition, and consults with the NFL-NFLPA Research and Education Foundation. He is recipient of the Stas Medal, awarded by the German Society of Toxicology and Chemistry and the Rolla Harger Award, an honor given by the American Academy of Forensic Sciences, Toxicology Section. In the fall of 1995 he received the Borkenstein Award from the National Safety Council for his more than 25 years of work on the role of alcohol and other drugs related to highway safety.
Bryan S. Finkle, Ph.D.cleancompetition2018-11-16T18:59:01-06:00
Dr. Bryan S. Finkle is a consultant in pre-clinical new drug development and medico-legal toxicology. For ten years, 1973-1983, Dr. Finkle was the Director of the Center for Human Toxicology at the University of Utah, and from 1983-1989 was Director of the Department of Pharmacology Sciences at Genentech, Inc. South San Francisco, California. During this period he was Associate Professor of Pharmacology-Toxicology in the College of Pharmacy, and Department of Pathology in the College of Medicine, University of Utah Health Sciences Center. Until 1996, Dr. Finkle was the Vice President for Development and Regulatory Affairs at Canji, Inc., a biotechnology company dedicated to gene therapy using tumor suppressor genes, novel cancer therapeutics and diagnostics. From 2000-02 he was associated with NewBiotics Inc., a biotechnology company dedicated to the development of enzyme catalyzed therapeutic agents. He continues to consult for medical biotechnology companies.